Apple to launch Apple Watch without oximetry in US in response to patent lawsuit

In response to the U.S. International Trade Commission (ITC) ruling on pulse oximetry patents, thepomegranateThe company has adopted an aggressive strategy. According to reports.pomegranateWe've begun shipping a "modified" version without the oxygen function to U.S. retailers.Apple Watch, to circumvent a possible sales ban.

Last year, the ITC ruled that Apple infringed on Masimo's pulse oximetry patents and ordered a ban on the importation and sale of Apple Watch models with oximetry sensing. However, Apple temporarily set aside the sales ban by means of an appeal. Nonetheless, last week the ITC has filed a complaint requesting that the sales ban be reinstated, putting more pressure on Apple.

In response to this challenge, Apple has adopted a strategy of adjusting its product configurations and algorithms. According to Bloomberg's Mark Gurman, Apple has begun shipping Apple Watch models without the oximetry feature to U.S. retail stores. The tweak is designed to avoid Masimo's patented technology, thereby avoiding further legal disputes and sales bans.

However, it remains to be seen whether Apple's strategy will be successful. The patent litigation with Masimo is likely to continue for some time, and Apple will need to continue to deal with possible legal challenges during this time. It is also a matter of concern whether the Apple Watch without the blood oxygen function will be able to meet the needs and expectations of users.

Apple's response to the patent lawsuit by launching an Apple Watch without oximetry demonstrates the company's flexible strategy in the face of legal pressure. However, the success of this strategy will depend on a number of factors, including the outcome of the lawsuit with Masimo, user feedback on the product, and market demand for an Apple Watch without oximetry.